GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...
GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...
Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...
Cambridge, USA-based Vesalius Therapeutics has entered into a multi-target strategic alliance with the UK’s GSK to discover ...
Plus: How AI can make it easier to find drugs from nature and a study suggests Ozempic could treat alcoholism.
The global artificial intelligence (AI) in drug discovery market is projected to reach USD 6.89 billion by 2029 from USD 1.86 ...
Third quarter results highlight strong operational performance across key value drivers: YUPELRI® (revefenacin) net sales of $62.2 million, recognized by Viatris ...
GSK recently acquired coeliac disease specialist ... a common mechanism in neurodegenerative conditions such as Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and Alzheimer’s ...
the drug is a reformulation of a standard Parkinson's treatment (carbidopa/levodopa) delivered by subcutaneous pump for hard-to-treat patients with advanced disease, and is in the latter stages of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback